Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Beto O’Rourke interrupts press conference on Texas school massacre
    • ECB warns a house price correction is looming as interest rates rise
    • Military briefing: Ukraine’s battlefield agility pays off
    • China’s premier issues stark warning on economy as growth stalls
    • Military briefing: battle for Sievierodonetsk shows Russian strategy in Donbas
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • EY plans global audit spin-off in drastic Big Four shake-up
    • Fed officials raised possibility of ‘restrictive’ policy to fight inflation
    • Elon Musk must find more cash for Twitter deal after scrapping margin loan
    • Beto O’Rourke interrupts press conference on Texas school massacre
    • On the waterfront: the political fight over organised crime at the Port of New York
  • Companies
    Sections
    • Companies Home
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
    Most Read
    • EY plans global audit spin-off in drastic Big Four shake-up
    • Elon Musk must find more cash for Twitter deal after scrapping margin loan
    • Klarna CEO says fintech will focus less on growth and more on ‘short-term profitability’
    • Pfizer warns of ‘constant waves’ of Covid as complacency grows
    • Vanguard refuses to end new fossil fuel investments
  • Tech
  • Markets
    Sections
    • Markets Home
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
    Most Read
    • Live news: Pentagon estimates Russia has lost nearly 1,000 tanks in Ukraine conflict
    • Live news updates from May 25: Musk must find cash for Twitter deal, Fed officials discussed ‘restrictive’ policy to fight inflation
    • Wall Street stocks make further gains after release of Fed minutes
    • Quant hedge funds reap windfall during 2022 market ructions
    • US house prices never go down
  • Climate
  • Opinion
    Sections
    • Opinion Home
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
    Most Read
    • Olivier Blanchard: ‘There’s a tendency for markets to focus on the present and extrapolate it forever’
    • Britain isn’t working. That should concern us all
    • No one is ready for the rising tide of climate litigation
    • Even Sue Gray’s scathing verdict is little threat to this prime minister
    • Partygate report reveals a prime minister unfit to lead
  • Work & Careers
    Sections
    • Work & Careers Home
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
    Most Read
    • Race at work: how hard are companies really trying?
    • Vive la différence between work and play
    • Why presenteeism is an enduring corporate narcotic
    • ‘A bonfire of the decencies’: Peter Hennessy on Boris Johnson’s government
    • The cold call is back and worse than ever
  • Life & Arts
    Sections
    • Life & Arts Home
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
    Most Read
    • The best of Cannes Film Festival 2022
    • ‘It’s not flavourless. It’s delicate and really, really nice’: the UK’s lager revolution
    • Kylie Minogue, uncorked
    • Tom Cruise is back in the cockpit for humdinger spectacle Top Gun: Maverick
    • The supposed method in El Salvador’s crypto madness
  • How to Spend It
MenuSearch
  • Home
  • World
  • US
  • Companies
  • Tech
  • Markets
  • Climate
  • Opinion
  • Work & Careers
  • Life & Arts
  • How to Spend It
Financial Times
SubscribeSign In

Your guide to a disrupted world

Start a 4-week trial

AstraZeneca PLC

Add to myFT Digest

Add this topic to your myFT Digest for news straight to your inbox

  • Friday, 29 April, 2022
    AstraZeneca sales beat forecasts on Covid jab demand

    Revenue rises 60% as Alexion acquisition and its rare diseases medicines boost drugmaker’s earnings

  • Wednesday, 20 April, 2022
    Oxford BioMedica PLC
    Oxford BioMedica warns revenue will be hit by AstraZeneca jab uncertainty

    Shares slide as London-listed group announces ‘pause’ in vaccine manufacturing

  • Wednesday, 6 April, 2022
    LexPharmaceuticals sector
    Breast cancer: precision drugs make inroads against stubborn tumours Premium content

    New therapies replace a blunderbuss with a stiletto

  • Thursday, 17 March, 2022
    Covid-19 vaccines
    AstraZeneca prepared to ditch effort to secure US approval for Covid vaccine

    UK drugmaker’s R&D chief says abandoning market would have little impact

  • Thursday, 10 February, 2022
    Covid vaccine helps push AstraZeneca to record revenues

    UK pharmaceuticals group raises dividend for first time in a decade

  • Thursday, 6 January, 2022
    Covid-19 vaccines
    Covid vaccine makers face investor pressure over global access

    Asset managers call for pharma executive pay to be linked to equitable distribution of jabs

  • Thursday, 23 December, 2021
    LexCovid-19 vaccines
    Oxford/AstraZeneca vaccine: underdog provider needs to pass potency test Premium content

    The apparent efficacy of its booster against Omicron could shore up the jab’s shaky position among competitors

  • Thursday, 23 December, 2021
    Covid-19 vaccines
    AstraZeneca booster raises antibodies against Omicron less than Pfizer, study shows

    Pharma group says it is confident its Covid vaccine ‘should be given as a third dose booster’

  • Tuesday, 21 December, 2021
    Covid-19 vaccines
    Oxford and AstraZeneca developing Omicron-targeted version of vaccine

    Global health authorities have voiced concern that current jabs may afford less protection against variant

  • Monday, 20 December, 2021
    Covid-19 vaccines
    Covid boosters essential to back up Oxford/AstraZeneca jabs, new study shows

    Protection against severe disease begins to wane three months after second shot

  • Thursday, 2 December, 2021
    Covid-19 vaccines
    UK’s ‘mix and match’ booster jab strategy backed by new study

    Research shows mRNA vaccines from Pfizer and Moderna are by far most effective third doses

  • Tuesday, 23 November, 2021
    Pascal Soriot links AstraZeneca jab to low UK hospitalisations

    Chief executive says more data needed to explain Europe’s higher rate of admissions

  • Tuesday, 23 November, 2021
    AstraZeneca calls on UK to increase science investment

    Chair of pharma group says support will boost economy as it opens £1bn R&D campus in Cambridge

  • Tuesday, 23 November, 2021
    FT live news
    News updates from November 23: US to release 50m barrels of oil from reserves, thousands in England sign up for Covid booster, Apple sues Israeli spyware group NSO
  • Friday, 19 November, 2021
    News in-depth
    AstraZeneca’s vaccine hopes lie overseas as it runs out of road in UK

    British drugmaker’s exclusion from booster campaign is latest setback

  • Tuesday, 16 November, 2021
    Covid-19 vaccines
    Top scientist defends decision to sell AstraZeneca vaccine at a profit

    Pharma group partnership with Oxford university hits 2bn-dose milestone

  • Friday, 12 November, 2021
    AstraZeneca to take profits from Covid vaccine sales

    Pharma group to move away from non-profit model used during pandemic

  • Tuesday, 9 November, 2021
    AstraZeneca commits to vaccines business with new division

    Move comes despite Anglo-Swedish group’s non-profit Covid-19 jab suffering setbacks earlier this year

  • Monday, 25 October, 2021
    Covid-19 vaccines
    Covid vaccines associated with rare neurological complications, says study

    Researchers emphasise that adverse events following Pfizer and AstraZeneca jabs are extremely rare

  • Friday, 22 October, 2021
    Lowball investor offer has AstraZeneca on tender hooks

    Vintage legal loophole comes back to haunt drugmaker; City crypto converts in demand; and COP26 takes to the water

  • Monday, 18 October, 2021
    Covid-19 vaccines
    Valneva says Covid jab yields stronger immune response than AstraZeneca’s

    Trial results come month after UK terminated contract with French company

  • Monday, 18 October, 2021
    LexMergers & Acquisitions
    Mini-tenders/AstraZeneca: regulatory loophole creates trap for the unwary Premium content

    Clearly, enough shareholders must accept lowball offers to make the effort worthwhile

  • Monday, 11 October, 2021
    AstraZeneca says Covid drug cuts risk of severe disease or death by 50%

    Advances by Merck and AstraZeneca raise hopes of bringing more treatments to market

  • Thursday, 23 September, 2021
    AstraZeneca partners with VaxEquity in RNA deal

    UK pharma group to commercialise 26 drug targets using technology proved by Covid vaccines

  • Friday, 10 September, 2021
    Covid-19 vaccines
    UK prepares for ‘mix and match’ Covid vaccine booster programme

    Government officials say using different jabs for third doses should provide better protection

Previous page You are on page 1 Next page

Topics related to Health & pharmaceuticals

Useful links

Support

View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

Legal & Privacy

Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

Services

Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT TransactSecondary Schools

Tools

PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

Community & Events

FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

More from the FT Group

Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
Financial Times

International Edition

Subscribe for full access
  • Switch to UK Edition
  • Top sections
  • Home
  • World
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
  • US
    • US Economy
    • US Companies
    • US Politics & Policy
  • Companies
    • Energy
    • Financials
    • Health
    • Industrials
    • Media
    • Professional Services
    • Retail & Consumer
    • Tech Sector
    • Telecoms
    • Transport
  • Tech
  • Markets
    • Alphaville
    • Markets Data
    • Capital Markets
    • Commodities
    • Currencies
    • Equities
    • Fund Management
    • Trading
    • Moral Money
    • ETF Hub
    • Cryptocurrencies
  • Climate
  • Opinion
    • Columnists
    • The FT View
    • The Big Read
    • Lex
    • Obituaries
    • Letters
  • Work & Careers
    • Business School Rankings
    • Business Education
    • Entrepreneurship
    • Recruitment
    • Business Books
    • Business Travel
  • Life & Arts
    • Arts
    • Books
    • Food & Drink
    • FT Magazine
    • House & Home
    • Style
    • Travel
    • FT Globetrotter
  • Personal Finance
    • Property & Mortgages
    • Investments
    • Pensions
    • Tax
    • Banking & Savings
    • Advice & Comment
    • Next Act
  • How to Spend It
  • Special Reports
  • FT recommends
  • Lex
  • Alphaville
  • Lunch with the FT
  • FT Globetrotter
  • #techAsia
  • Moral Money
  • FTfm
  • Newsletters
  • Video
  • Podcasts
  • News feed
  • FT Community
    • FT Live
    • FT Forums
    • Board Director Programme
  • myFT
  • Portfolio
  • Today's Newspaper (ePaper)
  • Crossword
  • Our Apps
  • Help Centre
  • Subscribe
  • Sign In